Literature DB >> 10901476

Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: toxicity and efficacy study.

K Imai1, A Loewenstein, B Koroma, R Grebe, E de Juan.   

Abstract

BACKGROUND: Proliferative vitreoretinopathy (PVR) is partially caused by peptide growth factors, stimulating the cell by binding to a transmembrane tyrosine kinase receptor. We studied the effects of herbimycin A (HA), a tyrosine kinase inhibitor, in PVR.
METHODS: Toxicity studies: Electroretinography and histological studies were performed after intravitreal injection of HA. Efficacy studies: Homologous rabbit dermal fibroblasts were injected intravitreally, followed by injection of HA. The presence of tractional retinal detachment (TRD) and severity of inflammation were assessed.
RESULTS: Toxicity studies: Eyes injected with HA exhibited decrease in B-wave amplitude initially, with subsequent recovery. Histologically, damage to photoreceptors was evident after injection of high but not of low doses of HA. Efficacy studies: Inflammatory response and the development of TRD were significantly reduced with all doses of HA.
CONCLUSIONS: HA (20 microM) was found to be effective and safe in preventing the development of inflammation and TRD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10901476     DOI: 10.1007/s004170050376

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  4 in total

1.  Effects of the protein tyrosine kinase inhibitor genistein and taurine on retinal function in isolated superfused retina.

Authors:  Matthias Lüke; Ralf Krott; Max Warga; Peter Szurman; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Toni Schneider; Christoph Lüke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02       Impact factor: 3.117

Review 2.  Proliferative Vitreoretinopathy: A Review.

Authors:  Sana Idrees; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2019

3.  The impact of octreotide in experimental proliferative vitreoretinopathy.

Authors:  Ozge Evren; Burak Turgut; Ulku Celiker; Kadir Ates
Journal:  Indian J Ophthalmol       Date:  2013-03       Impact factor: 1.848

4.  Proliferative vitreoretinopathy: current and emerging treatments.

Authors:  Ama Sadaka; Gian Paolo Giuliari
Journal:  Clin Ophthalmol       Date:  2012-08-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.